GlassScriptPhysician profile
Ansar Ullah Khan
NPI 1093794935
$15,068.44
in general payments reported to CMS, 2019-2025
44 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,980 · 2020: $1,076 · 2021: $1,476 · 2022: $1,543 · 2023: $3,494 · 2024: $2,254 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,748 · Travel and Lodging: $1,873 · Education: $267 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88.95 · Gift: $16.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,748.36 |
| Travel and Lodging | $1,873.09 |
| Education | $266.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88.95 |
| Gift | $16.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $2,296.14 | 2019-2020 | |
| Coloplast Corp | $2,180.71 | 2021-2025 | Speedicath |
| Angiodynamics, INC. | $1,856.30 | 2023 | Nanoknife |
| Astellas Pharma US INC | $1,550.69 | 2019-2025 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $1,155.21 | 2019-2025 | Erleada, Akeega |
| Abbvie INC. | $719.45 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $677.44 | 2023-2025 | Orgovyx, Gemtesa |
| Teleflex LLC | $587.91 | 2021-2023 | Urolift |
| Boston Scientific Corporation | $361.12 | 2019-2025 | Ams 700, General - Erectile Dysfunction |
| Healthtronics Stone Solutions, LLC | $325.38 | 2019-2021 | |
| Pfizer INC. | $296.04 | 2019-2025 | |
| Tolmar Pharmaceuticals, INC. | $257.23 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $231.69 | 2021-2025 | Provenge |
| Medtronic USA, INC. | $218.70 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.87 | 2019-2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ansar Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.